We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Effects of Inhibition of NO-Synthesis on Renal Hemodynamics and Sodium Excretion in Patients With Essential Hypertension and Healthy Controls

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00345150
Recruitment Status : Completed
First Posted : June 27, 2006
Last Update Posted : June 27, 2006
Information provided by:
Regional Hospital Holstebro

Brief Summary:
The study tests the hypothesis that systemic and renal nitric oxide synthesis is changed in essential hypertension by investigating the effects of a non selective nitric oxide inhibitor on renal hemodynamics and sodium excretion in patients with essential hypertension. The results are compared with a group of healthy subjects.

Condition or disease Intervention/treatment Phase
Hypertension Drug: Ng-monomethyl-L-arginine (drug) Phase 1

Detailed Description:

The study investigates the effects of Ng-monomethyl-L-arginine (L-NMMA) on:

  1. renal hemodynamics (renal plasma flow and glomerular filtration rate)
  2. renal sodium excretion
  3. lithium clearance and fractional lithium excretion
  4. plasma levels of vasoactive hormones
  5. blood pressure and heart rate

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single
Official Title: Phase 1 Study of the Effects of Systemic Nitric Oxide Inhibition With Ng-Monomethyl-L-Arginine on Renal Hemodynamics and Sodium Excretion in Patients With Essential Hypertension and Healthy Controls

Resource links provided by the National Library of Medicine

Drug Information available for: Arginine
U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Essential hypertension (blood pressure > 140/90) with no signs of secondary hypertension
  • P-creatinine < 200 µmol/L

Exclusion Criteria:

  • Anamnestic or clinical signs of heart disease, renal disease, liver disease, neoplastic disease, anemia or cerebro-vascular insult
  • Medication except antihypertensives
  • Drug or alcohol abuse
  • Pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00345150

Sponsors and Collaborators
Regional Hospital Holstebro
Principal Investigator: Jesper N Bech, MD, Ph.D. Dept. of Medicine, Holstebro Hospital, 7500 Holstebro, Denmark
Study Chair: Erling B Pedersen, Professor Holstebro Hospital, 7500 Holstebro, Denmark

ClinicalTrials.gov Identifier: NCT00345150     History of Changes
Other Study ID Numbers: MED.RES.HOS.1995.01.JNB
First Posted: June 27, 2006    Key Record Dates
Last Update Posted: June 27, 2006
Last Verified: June 2006

Keywords provided by Regional Hospital Holstebro:
nitric oxide
renal hemodynamics

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
Nitric Oxide
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Free Radical Scavengers
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Endothelium-Dependent Relaxing Factors
Vasodilator Agents
Protective Agents
Enzyme Inhibitors